Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Nitric oxide synthase (NOS) inhibitors and related tools act on the enzymes that make nitric oxide from L-arginine. NOS was first isolated from rat brain in 1990 and shown to require calmodulin for its activity. Three isoforms exist, neuronal, endothelial and inducible NOS (iNOS), the last expressed mainly in activated immune cells. 1400W dihydrochloride, described in 1997 as a slow, tight-binding iNOS inhibitor, and GW274150 are used for isoform-selective studies. L-NIO dihydrochloride is an arginine analog that inhibits several isoforms. Asymmetric dimethylarginine is an endogenous NOS inhibitor that accumulates in chronic renal failure. 2,4-Diamino-6-hydroxypyrimidine blocks GTP cyclohydrolase I, which limits synthesis of the NOS cofactor tetrahydrobiopterin.
Agmatine sulfate exerts modulatory action at multiple molecular targets, such as neurotransmitter systems, ion channels and nitric oxide synthesis. It is an endogenous agonist at imidazoline receptor and a NO synthase inhibitor.
Lobeglitazone is a novel thiazolidinedione-class compound and an orally active dual agonist of peroxisome proliferator-activated receptors (PPARs), with EC₅₀ values of 137.4 nM for PPARγ and 546.3 nM for PPARα. In addition to its metabolic effects, Lobeglitazone functions as an inhibitor of multiple pro-inflammatory and pro-fibrotic signaling pathways, including ERK, JNK, Smad, and NF-κB. Lobeglitazone exhibits a broad range of pharmacological activities, including anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic effects. These properties make it a promising candidate for therapeutic research in metabolic syndrome, type 2 diabetes, cardiovascular disease, and fibrosis-related conditions.
Lobeglitazone sulfate is a novel thiazolidinedione and an orally active agonist of peroxisome proliferator-activated receptors (PPARs), with EC50 values of 137.4 nM for PPARγ and 546.3 nM for PPARα. It also acts as an inhibitor of the ERK/JNK/Smad/NF-κB signaling pathways. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic activities, supporting its potential in the treatment of metabolic and inflammatory diseases.
7,8-Dihydro-L-biopterin serves as a nitric oxide synthase (NOS) uncoupling inducer and is capable of crossing the blood-brain barrier. As a reduced, non-conjugated pteridine and the primary metabolite of 4-amino-tetrahydro-L-biopterin, it promotes the conversion of NOS to a superoxide-producing form, elevating oxidative stress levels, particularly in the renal outer medulla, and triggering apoptosis. This compound's sensitivity to superoxide dismutase (SOD) inhibition makes it valuable for research into salt-sensitive hypertension, traumatic brain injury, and neurodegenerative diseases.
